top of page
< Back

Memphis News: St. Jude Snags $28.5M ARPA-H Grant to Fast-Track Life-Saving Gene-Editing Trials for Children

Direct Answer: St. Jude Children's Research Hospital has received up to $28.5 million from the federal Advanced Research Projects Agency for Health (ARPA-H) for the DRIVE project, accelerating personalized in vivo gene-editing therapies for children suffering from rare, life-threatening bone marrow disorders. St. Jude Children's Research Hospital is spearheading a major medical breakthrough with this newly awarded federal grant to launch human clinical trials for pediatric gene-editing...

Direct Answer: St. Jude Children's Research Hospital has received up to $28.5 million from the federal Advanced Research Projects Agency for Health (ARPA-H) for the DRIVE project, accelerating personalized in vivo gene-editing therapies for children suffering from rare, life-threatening bone marrow disorders. St. Jude Children's Research Hospital is spearheading a major medical breakthrough with this newly awarded federal grant to launch human clinical trials for pediatric gene-editing therapies within three years. Led by principal investigator Dr. Shengdar Tsai, the initiative represents a watershed moment for precision medicine right here in Memphis, Tennessee. By Dr. Layne McDonald, Founder of Memphis News with a Purpose Introduction: A Beacon of Hope on the Bluff City Horizon For decades, the name St. Jude has been synonymous with unyielding compassion, groundbreaking research, and a profound commitment to ensuring no child dies in the dawn of life. Today, that legacy reaches an exciting new milestone. Memphis is once again at the epicenter of global medical innovation as St. Jude secures up to $28.5 million from ARPA-H under the THRIVE (Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines) initiative. As a news organization rooted in both journalistic integrity and Christian values, we examine this monumental development not only through the lens of scientific achievement, but through the framework of divine stewardship, human ingenuity, and our calling to bring peace and healing to the most vulnerable among us. For readers exploring local stories and community updates, you can find more inspiring reports over at our Memphis News Blog. The DRIVE Project Explained: Precision Genome Editing Inside the Body To understand the magnitude of this award, we must examine the science behind the project. Named DRIVE (Delivering Rare-disease In Vivo Editors), the initiative focuses on rare pediatric bone marrow failure (BMF) syndromes. These devastating genetic conditions impair a child's ability to produce healthy blood cells, leading to severe, life-threatening complications. Traditionally, many gene therapies required harvesting cells from a patient, editing them in a laboratory incubator, and reinfusing them: a complex, grueling process. The DRIVE project, however, utilizes advanced CRISPR-based technology designed for in vivo delivery. This means the gene-editing tools are delivered directly into the patient's body to correct disease-causing DNA mutations right at their source. Led by Dr. Shengdar Tsai, a renowned hematology and genome-editing researcher at St. Jude, the team is deploying the most sensitive and accurate off-target detection methods available. By ensuring extraordinary precision, the research aims to eliminate unintended genetic alterations while correcting the root cause of inherited bone marrow failure. The Innovative Umbrella Clinical Trial Model One of the most remarkable aspects of the ARPA-H-funded THRIVE initiative is its structure. Rather than forcing researchers to go through separate, isolated clinical trials for every single rare genetic mutation: a process that can take decades and cost millions: DRIVE employs an umbrella clinical trial model. Under this innovative framework, multiple gene-editing products targeting different rare bone marrow failure syndromes will share a unified trial infrastructure. They will share common biodistribution profiles, toxicology standards, and safety monitoring frameworks. This streamlined approach is designed to dramatically accelerate the timeline from laboratory discovery to patient bedside. St. Jude’s ambitious milestone is to transition from preclinical research to first-in-human clinical trials within roughly three years of the grant's start date. For families navigating harrowing medical diagnoses, this speed is nothing short of miraculous. Memphis as a Global Hub for Pediatric Medical Innovation This $28.5 million federal investment is a testament to why Memphis stands tall on the international stage. While cities across the nation compete in technology and finance, Memphis holds a unique and sacred distinction: we are a sanctuary of healing. From the world-class research labs at St. Jude to community-driven initiatives like the FedEx St. Jude Championship and local charitable partnerships, our city consistently demonstrates a collective heart for service. Whether we are covering local sports traditions or civic milestones: such as those highlighted in our coverage of Memphis community outreach and regional events: Memphians know how to rally together around a purpose greater than ourselves. Understanding ARPA-H and the National Impact The Advanced Research Projects Agency for Health (ARPA-H) was established to drive high-impact biomedical breakthroughs that commercial markets alone might not tackle quickly enough. Through its THRIVE program, ARPA-H has committed up to $160 million across seven elite research teams nationwide. St. Jude’s selection for the bone marrow failure portfolio reflects its unmatched expertise in pediatric hematology. When federal backing meets institutional dedication, the result is a powerful catalyst for change. As local readers and business leaders, supporting and understanding these scientific milestones helps us appreciate the depth of talent working quietly inside our city limits every single day. ❓ Frequently Asked Questions What is the DRIVE project? The DRIVE (Delivering Rare-disease In Vivo Editors) project is a St. Jude-led initiative funded by ARPA-H to develop unified in vivo gene-editing platforms for rare pediatric bone marrow failure syndromes. How much funding was awarded to St. Jude? St. Jude received up to $28.5 million over several years to support the DRIVE research program. What is ARPA-H? The Advanced Research Projects Agency for Health is a federal agency within the U.S. Department of Health and Human Services dedicated to funding high-reward, high-risk biomedical research. When are human clinical trials expected to begin? Under the THRIVE umbrella trial framework, St. Jude aims to advance the gene-editing platform into first-in-human clinical trials within approximately three years. Who is leading the research team? The research is led by Dr. Shengdar Tsai, Ph.D., an expert in hematology and genome editing at St. Jude Children's Research Hospital. Christian Takeaway Psalm 139:14 declares with breathtaking clarity: "I praise you, for I am fearfully and wonderfully made. Wonderful are your works; my soul knows it very well." Human DNA is an intricate masterpiece of divine design. When genetic mutations disrupt this design, causing profound suffering in children, it breaks our hearts: and it breaks the heart of our Creator. Yet God has equipped human minds with creativity, intelligence, and compassion to explore, discover, and heal. Scientific discovery and medical innovation are profound reflections of our calling to alleviate suffering and protect the vulnerable. When brilliant researchers at St. Jude dedicate their lives to curing genetic diseases, they are participating directly in God's restorative work in the world. They are bringing light into dark places and offering tangible hope to families walking through unimaginable storms. How to Pray and Engage As a community of faith and engaged citizens, we can actively participate in this mission: Pray for Healing and Wisdom: Lift up the children and families facing rare bone marrow disorders. Pray also for Dr. Shengdar Tsai and the entire research team at St. Jude, asking God to grant them wisdom, clarity, and breakthrough success in their laboratory and clinical trials. Support Local Missions: Consider volunteering, donating, or participating in local community fundraisers that support St. Jude's mission of providing cutting-edge care without financial burden to families. Be a Peacemaker: Share words of encouragement with parents and caregivers in your neighborhood who may be quietly carrying the heavy burden of a child's medical crisis. Remind them they are not alone. Peacemaker's Perspective In times of medical uncertainty and scientific debate, it is easy to become divided or cynical. However, stories like St. Jude's ARPA-H grant remind us of what is possible when society unites around a common, noble purpose: the protection and healing of children. A peacemaker in the storm does not look away from suffering; instead, they step into the breach with compassion, support, and hope. By championing life-saving innovation and supporting institutions that serve the vulnerable, Memphis continues to shine as a city of refuge and renewal. Share this article with a friend, family member, or fellow Memphian who supports the life-saving mission of St. Jude! Call to Action: How does medical innovation inspire hope in your family, and how can we as a community better support families facing medical storms? Let us know your thoughts in the comments below, and visit our Memphis News Blog for more uplifting stories!

memphis-news-st-jude-snags-28-5m-arpa-h-grant-to-fast-track-life-saving-gene-editing-trials-for-c

bottom of page
Choose Language